fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Pegfilgrastim

All injection strengths: general benefit

Ziextenzo · DIN 02497395 · 6 mg/0.6 mL · injection, 0.6 mL pre-filled syringe (preservative-free)

General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Ziextenzo · DIN 02497395 Manufacturer: Sandoz Canada Inc.; listing date 2020-08-28 Health Canada: Marketed since 2020-05-15 · brand ZIEXTENZO · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 6 MG/0.6ML · company Sandoz canada incorporated · schedule Prescription, Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

Ziextenzo: Formulary list price $492.00 per unit (the source does not state the unit; exact figure $492.0000). What the ministry pays, not the patient.

Ministry pays: $492.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02497395)

Source record
DIN 02497395: Ziextenzo Raw flags: sec3=Y Item: 201600060; group id 270; item number 0555; lccId None; manufacturer id SDZ Source form: Inj Sol-0.6mL Pref Syr (Preservative-Free); strength: 6mg/0.6mL Recorded listing: General benefit Source prices (unrounded): $492.0000; ministry $492.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02497395 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98722
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (L03AA): coverage varies; not interchangeable

  • Filgrastim (Nivestym): general benefit
Other drugs in the same formulary class (20:16 Hematopoietic Agents) and how they are covered

Matched class: 20:16 Hematopoietic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FILGRASTIM 20:16 Hematopoietic Agents

FILGRASTIM

· 10 products · General benefit · strengths: 300mcg/0.5mL, 480mcg/0.8mL, 480mcg/1.6mL, 300mcg/mL · Inj Sol-0.5mL Pref Syr, Inj Sol-0.5mL Pref Syr (Preservative-Free), Inj Sol-0.8mL Pref Syr, Inj Sol-0.8mL Pref Syr (Preservative-Free), Inj Sol-1.6mL Vial Pk, Inj Sol-1mL Vial Pk, Pref Syr-0.5mL Pk, Pref Syr-0.8mL Pk

DARBEPOETIN ALFA

· 4 products · Limited Use, codes 420 · strengths: 150mcg/0.3mL, 200mcg/0.4mL, 300mcg/0.6mL, 500mcg/1.0mL · Pref Syr-0.3mL Pk, Pref Syr-0.4mL Pk, Pref Syr-0.6mL Pk, Pref Syr-1.0mL Pk

EPOETIN ALFA

· 3 products · Limited Use, codes 420 · strengths: 10,000IU/mL, 40,000IU/mL, 20,000IU/0.5mL · Pref Syr - 1mL Pk, Pref Syr-0.5mL Pk

ELTROMBOPAG OLAMINE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 20:16
Full class listing Related classes: 20:04 Antianemia Drugs, 20:12 Coagulants and Anti-Coagulants, 20:24 Hemorrheologic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications LAPELGA® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti- neoplastic drugs. 1.1 Pediatrics (< 18 years of age) No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics (> 65 year of age) No data are available to Health Canada; therefore Health Canada has not authorized on indication for geriatric use. https://pdf.hres.ca/dpd_pm/00083321.PDF PM date: 2026-01-29 Source product: LAPELGA; DIN 02474565; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.